Key result
Oxysterol stimulation normalizes defective phospholipid efflux and alpha-HDL formation in severe HDL deficiency.
Why the study?
Severe HDL-C deficiency is attributed to mutations in several genes and may contribute to the genetic basis of coronary artery disease, prompting investigation to identify the cellular basis of a novel HDL-deficiency phenotype.
Does oxysterol stimulation normalize defective cellular phospholipid efflux and ABCA1 protein expression in fibroblasts from patients with severe HDL deficiency?
Observational (n=54)
Does oxysterol stimulation normalize defective cellular phospholipid efflux and ABCA1 protein expression in fibroblasts from patients with severe HDL deficiency?
Demonstrates for the first time in humans that cellular phospholipid and cholesterol efflux are distinct processes in HDL biosynthesis and that defective ABCA1-regulated phospholipid efflux can be corrected in vitro by oxysterols.
Answers are grounded in this paper and cite their sources.
Oxysterol correction of phospholipid efflux remains experimental; leaves open whether ABCA1 modulation offers a therapeutic target in severe HDL deficiency.
AIMS: Severe high-density lipoprotein cholesterol (HDL-C) deficiency is attributed to mutations in several genes and may contribute to the genetic basis of coronary artery disease. To identify the cellular basis of a novel HDL-deficiency phenotype, we screened 54 subjects of French Canadian ancestry with severe HDL deficiency. METHODS AND RESULTS: We excluded individuals with mutations in genes currently associated with low HDL (ABCA1, LCAT, APOA-I, and SMPD1). We identified two patients in which cellular phospholipid efflux in the HDL biosynthesis process is impaired, whereas cholesterol efflux is normal. Two-dimensional gel electrophoresis analysis further showed that the two patients with impaired phospholipid efflux were defective primarily in the larger alpha-HDL subpopulations. In fibroblasts from affected subjects, oxysterol stimulation resulted in increased ABCA1 protein expression and normalized their defective phospholipid efflux defect. CONCLUSION: Our results indicate for the first time in humans that phospholipid and cholesterol efflux are two separate and distinct processes in cellular HDL biosynthesis. They further show for the first time that normal cellular phospholipid efflux is necessary for the formation of larger alpha-HDL particles. The defect in phospholipid efflux is due to defective ABCA1 protein regulation and can be corrected by treatment with physiological oxysterols, a current therapeutic target of interest, that may, with further studies, be used to raise HDL levels in patients with severe HDL deficiencies.
No takes yet. Share an insight, caveat, or question.
Marcil et al. (2009) conducted an observational in Severe high-density lipoprotein cholesterol (HDL-C) deficiency (n=54). Oxysterol stimulation (in vitro in fibroblasts) was evaluated on Cellular phospholipid efflux, cholesterol efflux, and alpha-HDL subpopulation formation. Screening 54 severe HDL-deficient subjects identified 2 patients with impaired cellular phospholipid efflux and reduced large alpha-HDL particles, which normalized with oxysterol stimulation.
Synapse has enriched 10 related papers. Consider them for comparative context: